GlassScriptPhysician profile
Misty D White
NPI 1912408469
$8,016.13
in general payments reported to CMS, 2019-2025
47 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,897 · 2022: $966 · 2023: $1,528 · 2024: $2,053 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,152.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $2,014.33 | 2021-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $750.18 | 2021-2025 | Xtampza, Belbuca |
| Abbvie INC. | $564.74 | 2022-2025 | |
| Pfizer INC. | $527.36 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $399.79 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Forte Bio-Pharma LLC | $346.75 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Novartis Pharmaceuticals Corporation | $345.63 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.02 | 2021-2025 | Relistor |
| Valinor Pharma, LLC | $227.30 | 2024-2025 | Movantik |
| Upsher-Smith Laboratories LLC | $216.94 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $186.47 | 2021 | |
| Abbott Laboratories | $169.89 | 2023-2025 | Eterna, Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $162.05 | 2022 | |
| Horizon Therapeutics Plc | $136.73 | 2021-2022 | |
| Lilly USA, LLC | $133.57 | 2023-2025 | Emgality, Reyvow, Kisunla |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.